/l with 47% plasma cells. These plasma cells had multiple and irregular lobulated nuclei. The marrow as infiltrated with 55% plasma cells and the bone marrow plasma cells karyotype was 48,XX,+3,i(7)(q10),dic(9;?)(q34;?),−10,−13,−14,+21,+? 22,+3 mar (five metaphases). Electrophoresis and immunoelectrophoresis of serum showed an IgG kappa M-component (68 g/l).
The patient initially received five monthly cycles of VAD chemotherapy (vincristin, doxorubicin, dexamethasone). Then, an allogeneic bone marrow transplantation (BMT) was performed in December 1993 with her HLA-identical brother. The conditioning regimen consisted of cyclophosphamide (120 mg/kg), melphalan (140 mg/m 2 ) and total body irradiation (TBI, 12 Gy). Cyclosporin A and methotrexate were used as graft-versus-host disease (GVHD) prophylaxis and no GVHD was observed. Complete remission was achieved following allogeneic BMT. In June 1994, 6 months following BMT, electrophoresis and immunofixation of serum and urine showed no paraprotein, bone marrow was normal (1% plasma cells with normal morphologic features) and bone marrow karyotype was 46,XY in 36 metaphases.
In August 1994, she was hospitalized for paresthesia of the right leg which bilateralized. An electromyographic study was in favor of a mild sensorimotor peripheral neuropathy. At this time, the patient still received low doses of cyclosporin A and a toxic neuropathy was suspected. Despite the discontinuation of cyclosporin A, the neurologic symptoms persisted and the patient was hospitalized 2 weeks later for sudden paraplegia with sphincter disturbance. Magnetic resonance imaging showed a homogeneous hyperintense intradural mass on sagittal gadolinium enhanced T1 weighted image, posterior to the The patient rapidly underwent laminectomy with decompression removing a plasma cell tumor. Multiple nerves from caudal spine were involved. Cerebrospinal fluid examination found an elevation of total protein (45 g/l) and 2800 cells/mm 3 , all plasma cells. These cells had the same morphological abnormalities as the plasma cells observed in the peripheral blood at diagnosis, especially large lobulated nuclei. Thus, the diagnosis of an isolated neurological relapse was made 8 months after BMT. There was no evidence of hematological relapse. The patient had no detectable M-component in the serum. The bone marrow was normal and the karyotype was of male donor type (four metaphases). Local radiotherapy (20 Gy) was delivered, but soon after the completion of the irradiation the patient was hospitalized because of a mass developing behind the right knee with pain and swelling of the leg (Figure 2a ).
The biopsy of this mass confirmed the diagnosis of plasmocytoma. Local radiotherapy (36 Gy) was again delivered, followed by chemotherapy with melphalan and dexamethasone. Despite this treatment, the disease worsened with increase of the tumor mass in the right leg ( Figure 2b ). Leg plasmocytomas became bilateral (data not shown). The patient successively received various chemotherapy protocols including vinorelbine, cyclophosphamide and etoposide 4 and EDAP (etoposide, dexamethasone, cytosine arabinoside, cisplatinum) 5 without any improvement. Death occurred in May 1995 from progressive disease.
A 68-year-old woman presented in April 1995 with primary PCL. WBC count was 24.5 × 10 9 /l with 63% plasma cells. The marrow was infiltrated with 33% plasma cells with normal karyotype using conventional cytogenetics. Electrophoresis and immunoelectrophoresis of serum showed an IgG kappa M-component (39 g/l). The treatment consisted of four monthly cycles of VAD followed by an autologous peripheral blood stem cell transplantation performed in October 1995. The conditioning regimen consisted of melphalan alone at the dosage of 140 mg/m 2 . Complete remission was achieved. In May 1996, the patient presented with vertigo related to a cerebellar syndrome. Cerebral MR imaging revealed two hyperintense lesions on axial gadolinium enhanced T1 weighted image in the cerebellar hemispheres (Figure 3 ). MR imaging of the spine was also performed and showed an epidural lesion at the T8 and T9 level (not shown). The lumbar puncture revealed a slight increase of protein (1.2 g/l) and 380 cells/mm 3 , all atypical plasma cells. Blood count, bone marrow examination, electrophoresis and immunoelectrophoresis of serum and urine were normal, confirming the persistence of the hematological remission. Diagnosis of extramedullary relapse, predominantly cerebellar and occurring 7 months after autograft was made. Over the next 9 months, the patient received intravenous EDAP chemotherapy (two cycles in May and July 1996), intrathecal chemotherapy with methotrexate Gadolinium enhanced T1 weighted image showing two homogeneous hyperintense lesions close to the fourth ventricle.
(15 mg) and cytosine arabinoside (50 mg) (five injections) and radiotherapy (18 Gy craniospinal plus 34 Gy on T8-9 epiduritis). A transient but clear clinical and biological improvement occurred after the first cycle of EDAP combined with intrathecal chemotherapy. All neurological signs disappeared and cerebrospinal fluid normalized. Nevertheless, treatment was complicated by severe infections. Repeated episodes of confusion were also observed. Death occurred in February 1997 from myelomatous meningoencephalitis. No bone marrow examination was performed between May 1996 (time of relapse) and death. Nevertheless, serum and urine paraprotein remained undetectable and there was no evidence of blood plasma cells until death.
Meningeal involvement has been reported in multiple myeloma and primary PCL (Refs 6-8 and review in Ref. 9). Patients in whom plasma cells are detectable in the peripheral blood, albeit in quantities insufficient for the diagnosis of PCL have been considered at increased risk of central nervous system (CNS) involvement. 8 To our knowledge, isolated CNS relapse after intensive treatment has never been reported. Between October 1988 and December 1997, 13 allogeneic and 118 autologous transplants were performed in our department for multiple myeloma patients. None of these patients had a CNS relapse. Apart from the two patients reported in this letter, only one other patient received an intensive treatment for primary PCL (an autologous transplant) and this patient died from hematological relapse. The most striking feature in our two patients was the absence of hematological relapse concomitant with the CNS relapse. Furthermore, it can be considered that CNS relapse remained isolated until death. In patient 1, the IgG kappa M-component was detectable at the terminal phase of the disease at a time where the right leg plasmocytoma was enormous. Therefore, it is likely that the paraprotein was derived from this major plasmocytoma and this hypothesis is reinforced by the absence of plasma cells in the bone marrow and the blood at this time, associated with a normal male karyotype in all examined cells. In patient 2, dorsal epiduritis was observed in conjunction with the cerebral lesion, but there was no evidence of hematological relapse until death.
Survival from relapse was short despite intensive treatment, especially chemotherapy, given in these transplanted patients. CNS relapse probably emerged from resistant plasma cells which escaped the cytoreductive chemotherapy and conditioning regimen. In fact, high-dose melphalan, the main drug of inensive treatment in myeloma, does not cross the blood-brain barrier. [10] [11] [12] [13] Taken together, these observations suggest that neuro-meningeal prophylaxis including cranial radiotherapy should be part of the intensive treatment of primary PCL. The best intrathecal prophylaxis would have to be determined. Intrathecal methotrexate and cytarabine, which are effective in the treatment of leukemic meningitis, are not efficacious for myelomatous meningitis.
14 Nevertheless, they could have a role as prophylaxis, especially cytarabine. In patient 2, cytarabine, given intrathecally and as part of the EDAP protocol, probably contributed to the transient normalization of the cerebrospinal fluid. Thiotepa, which is a cell cycle-insensitive alkaylting agent has also been given by the intrathecal route for treatment of meningeal myelomatosis and could be proposed for prophylaxis. 15 Finally, these reports raise the issue of routine cerebrospinal fluid examination and CNS magnetic resonance imaging in patients with primary PCL at diagnosis. + , n = 16) followed up longitudinally for 3 years.
ALL patients, who received treatment as per the UKALLVIII protocol, were bled at different phases of therapy. Peripheral blood mononuclear cells were isolated and cultured with ATN H (0.05-12 g) for 96 h followed by an 18 h pulse with 3 H-TdR. Radioactivity incorporated, in individual samples, was plotted against ATN H dose and the dose corresponding to maximal incorporation of radioactivity was designated as its 'maximal lymphoproliferative dose' (MLD). The MLD was employed to evaluate the percentage recovery of individual patients.
The variation in MLD values for individual patients, under different phases of treatment is shown in Table 1 and employed as an index to determine their % recovery. The pretreatment MLD, for all patients, ranging from 0.1 to 0.25 g, represented 0% recovery and reflected a possible increased expression of 9-OAcSGs. Following therapy, the MLD progressively increased to 1-2 g during consolidation/early intensification (4-8 weeks) and 3-8 g in maintenance therapy (8 weeks-2 years). The increasing MLD indicated an
